PubMed Health⌕ Search

Biomedical subjects

W Waters

Publications and source records attributed to W Waters.

16 recordsLinked to original sources
PubMed1991

Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial.

From 1984 to 1989, 47 children with relapsed, refractory, and/or metastasized neuroblastoma were treated with 131I-metaiodobenzylguanidine (mIBG) in several different treatment combinations. At initial diagnosis, 36 children had Evans stage IV and 11 stage III disease. In 16 of the 47 children, tumor recurred after complete remission prior to mIBG treatment, 26 of 47 progressed from residual or nonresponding tumor, and in 5 of 47 tumor progression during chemotherapy was observed. Altogether the children were treated with a total of 112 courses (range 1-6) with a mean dosage of 8.9 +/- 6.7 mCi/kg body weight/treatment course. Total dose was 283.2 +/- 203.7 mCi for stage III and 388.9 +/- 218.6 mCi for stage IV. Nine of 47 children reached a complete or a very good partial remission (CR and VGPR) from mIBG treatment alone, 13 of 47 achieved partial remission (PR). In an early analysis, 10 patients treated with mIBG in the neuroblastoma trial NB 85 of the German Society of Pediatric Oncology showed no significant difference in survival time compared with 30 conventionally treated children. However, the recent therapy series has been done with higher doses of mIBG, and during improved therapeutic scanning many more bone lesions could be detected than during earlier diagnostic scanning. We conclude that mIBG treatment has not yet fulfilled the expectations for it but still seems for certain indications to be a promising tool to treat neuroblastoma in the future. Moreover, the frontier of neuroblastoma detection is still advancing.

3-Iodobenzylguanidine↗
PubMed1991

[The effect of hyper- and hypothyroidism on the energy metabolism of skeletal muscles--a study using 31P-magnetic resonance spectroscopy].

31P magnetic resonance spectroscopy allows non-invasive evaluation of phosphorus metabolism in man. The purpose of the present study was to assess the influence of hyper- and hypothyroidism on the metabolism of resting human skeletal muscle. The present data show that quantitative measurement of phosphate metabolism by NMR is possible as also demonstrated by other studies. Using a quantitative evaluation method with an external standard, significant differences in the levels of phosphocreatine, adenosine triphosphate, and phosphodiesters were found. In hypothyroid patients a TSH-dependent increase in phosphodiesters and a decrease in adenosine triphosphate and phosphocreatine was observed. In hyperthyroidism a similar decrease in adenosine triphosphate but a considerably higher decrease in phosphocreatine occurred. In the light of the results of other studies of muscle metabolism, these changes appear to be non-specific so that further studies are required to assess the clinical value of such measurements.

Adenosine Triphosphate↗
PubMed1990

[Neopterin as a marker of aspecific immunostimulation with Propionibacterium avidum KP-40 in patients with gastrointestinal tumors. A prospective randomized study].

This prospective randomized study demonstrated that a preoperative intravenous infusion of 10 mg of the bacterial preparation Propionibacterium avidum KP-40 to patients with gastrointestinal tumors significantly (P less than 0.001) enhanced the secretion of neopterin, measurable as long-lasting (greater than 16 days) elevated urine excretion. Postoperative re-infusion of P. avidum KP-40 caused (statistically significant (p less than 0.001] re-enhancement of neopterin urine levels.

Adult↗
PubMed1990

Immunoscintigraphic imaging of mIBG-negative metastases in neuroblastoma.

We report a study of seven children with recurrent stage IV neuroblastoma comparing the uptake pattern of 123I-metaiodobenzylguanidine (mIBG) with 99mTc-labeled monoclonal antibody (MAb) BW 575 by the tumor lesions. Immunofluorescence studies of bone marrow had verified specific binding of the antibody to the tumor cells. The majority of tumor sites was detected both by mIBG and MAb scans. However, five of 26 lesions were not detected by mIBG and eight of 26 were false negative by immunoscintigraphy. The false negative lesions by mIBG belonged to five different patients (one of five primary, four of five bone marrow). In conclusion, MAb BW 575 may detect mIBG-negative neuroblastoma sites. The presence of antibody-negative sites suggests the utilization of both scintigraphy methods together.

3-Iodobenzylguanidine↗
PubMed1986

Transplantation of cryopreserved hepatocytes or liver cytosol injection in the treatment of acute liver failure in rats.

Intraperitoneally injected cryopreserved hepatocytes or liver cytosol were used for the treatment of acute galactosamine-induced liver failure in rats. Both methods were similarly capable to improve the survival rates as compared to control groups. Furthermore, a new viability test for transplanted hepatocytes, using a nuclearmedical tracer technique, was evaluated in this study. This test demonstrated viability of intraperitoneally transplanted hepatocytes for at least 6 days after operation. Cytosol injection should be preferred to hepatocyte transplantation in the treatment of acute liver failure, avoiding the problems of cell storage and post-transplant immunosuppression.

Acute Disease↗
PubMed1986

Three-dimensional imaging in medicine: holography.

Two holographic methods for three-dimensional imaging in medicine are presented. The methods can be applied on the base of various primary projection methods, especially those of nuclear medicine and roentgenology. This three-dimensional display, which is not bound to complicated technical equipments such as computers and graphic displays, can be performed easily at any place: in conference rooms, in surgical units etc. It may be of particular importance for the surgeon in order to visualize the site directly and in its real space dimensions.

Holography↗
PubMedDate not supplied

[131(I)-meta-iodobenzylguanidine treatment of 32 children with therapy-refractory neuroblastoma].

The selective uptake and accumulation of 131J-Metaiodobenzylguanidine in neuroblastoma cells in vivo may be utilized for targeted irradiation. The experience with 32 neuroblastoma patients refractory to conventional high dose chemotherapy is reported. At diagnosis 8 patients had Evans stage III and 22 stage IV. 11/32 experienced recurrences after complete tumor disappearance and before mIBG treatment, 16/32 progressed from residual or nonresponding tumor and in 3/32 insufficient tumor regression by chemotherapy was observed. 2 children received one mIBG course each with no evidence of disease. Mean applied activity was 128 mCi per course (35-300 mCi), 360 mCi per patient (80-1033 mCi) and 19.2 mCi/kg per patient (3.2-37.9 mCi/kg), respectively. A total of 84 courses was given (mean 2.6 per patient). Pain relief was noticed in 14/14 patients with bone pain. Complete or very good partial remission was achieved in 5/32, partial remission in 11/32 and stable disease in 6/32 patients. In 8 children progression occurred and 2 patients were not evoluable. 20 children died, 12 are still alive (6 patients with initial stage IV, 6 with stage III disease). Main side effect was transient thrombocytopenia, which became more severe with increasing number of courses. We conclude that mIBG treatment is effective in some patients with refractory neuroblastoma and may be utilized in the future as front line therapy for patients achieving only incomplete regressions after high dose chemotherapy.

3-Iodobenzylguanidine↗